6XS Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€4.99M
Enterprise ValueN/A
Total Cash (Recent Filing)€213.63K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Jun 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding6,327,666,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Leadership ChangeThe appointment of Olivia Edwards as Executive Chairperson is positive due to her strategic financing experience, which could guide the company through financial challenges and align growth strategies.
Debt-Free Balance SheetA debt-free balance sheet provides financial flexibility and reduces risk, allowing the company to focus on operational improvements and strategic investments without the burden of debt obligations.
Product InnovationThe company's focus on biosynthetic cannabinoids for skincare and wellness products positions it well in a growing market, potentially driving future sales growth and enhancing competitive advantage.
Bears Say
Profitability ChallengesOngoing profitability issues, as indicated by negative EBIT and profit margins, highlight operational inefficiencies that could hinder long-term financial sustainability if not addressed.
Negative Cash FlowNegative cash flow reflects challenges in converting revenue to cash, which can limit the company's ability to invest in growth opportunities and maintain operations without external funding.
Declining EquityDeclining equity indicates potential financial instability, reducing the company's ability to absorb losses and invest in growth, which could impact long-term viability if not reversed.
Astrid Intelligence News
6XS FAQ
What was Astrid Intelligence PLC’s price range in the past 12 months?
Astrid Intelligence PLC lowest stock price was <€0.01 and its highest was €0.03 in the past 12 months.
What is Astrid Intelligence PLC’s market cap?
Astrid Intelligence PLC’s market cap is €4.99M.
When is Astrid Intelligence PLC’s upcoming earnings report date?
Astrid Intelligence PLC’s upcoming earnings report date is Jun 02, 2027 which is in 303 days.
How were Astrid Intelligence PLC’s earnings last quarter?
Astrid Intelligence PLC released its earnings results on May 18, 2026. The company reported -€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.001.
Is Astrid Intelligence PLC overvalued?
According to Wall Street analysts Astrid Intelligence PLC’s price is currently Overvalued.
Does Astrid Intelligence PLC pay dividends?
Astrid Intelligence PLC does not currently pay dividends.
What is Astrid Intelligence PLC’s EPS estimate?
Astrid Intelligence PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Astrid Intelligence PLC have?
Astrid Intelligence PLC has 6,327,666,000 shares outstanding.
What happened to Astrid Intelligence PLC’s price movement after its last earnings report?
Astrid Intelligence PLC reported an EPS of -€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Astrid Intelligence PLC?
Currently, no hedge funds are holding shares in DE:6XS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Astrid Intelligence PLC
Cel AI PLC, together with its subsidiaries, engages in the manufacture and sale of biosynthetic cannabinoids-based consumer products in the United Kingdom. The company provides cannabinoid solutions for skincare and ingestible products. It offers its products through retailers; direct to consumers through its website; and online. The company was formerly known as Cellular Goods PLC and changed its name to Cel AI PLC in February 2024. Cel AI PLC was incorporated in 2018 and is based in London, United Kingdom.